ESMO Immuno-Oncology Congress 2022
![2022_crowd 1](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/2022_crowd-1/16105284-1-eng-GB/2022_crowd-1_i770.jpg)
Preliminary activity is reported with an anti-IL-8 monoclonal antibody plus nivolumab in melanoma
Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors
![IO2022_5](/var/esmo/storage/images/media/esmo-daily-reporter/images/immuno-oncology-2022/io2022_5/16152429-1-eng-GB/io2022_5_i770.png)
Combined biomarker analysis shows promise as a tissue agnostic response predictor for immunotherapy-based treatment
Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone
![Public 6](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/public-6/9274557-1-eng-GB/public-6_i770.jpg)
Two studies explore new predictive biomarkers for immunotherapy in NSCLC
Different methods – multiparametric biomarker assessment and FDG-PET – show mixed accuracy and their applicability in clinical practice needs to be assessed
![IO2022_4](/var/esmo/storage/images/media/esmo-daily-reporter/images/immuno-oncology-2022/io2022_42/16116792-1-eng-GB/io2022_4_i770.png)
Do immune checkpoint inhibitors affect COVID-19 severity?
A joint analysis of the OnCovid and ESMO-CoCARE registries confirms the protective role of anti-SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
![IO2022_2](/var/esmo/storage/images/media/esmo-daily-reporter/images/immuno-oncology-2022/io2022_2/16116246-1-eng-GB/io2022_2_i770.png)
Positive preliminary results for combination therapy with adagrasib in KRAS G12C-mutated NSCLC
Phase III trials are planned to assess combined KRAS G12C inhibition/checkpoint inhibition as first-line therapy
![IO_2022_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/immuno-oncology-2022/io_2022_01/16115649-1-eng-GB/io_2022_01_i770.png)
Neoadjuvant anti-PD-L1/TGFβRII fusion protein facilitates surgery in unresectable NSCLC
Phase II study indicates that SHR-1701 alone or together with chemotherapy may be a valuable induction strategy in stage III unresectable NSCLC
![IO2022_3](/var/esmo/storage/images/media/esmo-daily-reporter/images/immuno-oncology-2022/io2022_3/16116777-1-eng-GB/io2022_3_i770.png)
Neoadjuvant camrelizumab plus chemotherapy improves pathologic complete response in stage IIIA and B NSCLC
Positive results from a phase II trial adds weight to the value of immunotherapy as neoadjuvant treatment for resectable NSCLC
![2022_public 3](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/2022_public-3/16105389-1-eng-GB/2022_public-3_i770.jpg)
Exploratory analysis of IMpower010 confirms that ctDNA is prognostic for adjuvant atezolizumab in NSCLC
However, improved outcomes are reported in PD-L1-positive patients only irrespective of post-operative and post-chemotherapy ctDNA status, calling into question its predictive value
![DR_mobile_FOR EDITORIALS](/var/esmo/storage/images/media/esmo-daily-reporter/images/dr_mobile_for-editorials/12211793-1-eng-GB/dr_mobile_for-editorials_i770.jpg)
Back to basics: do we need more immuno-oncology in the core curriculum?
Due to the current widespread use of immunotherapies and their increasing complexities, further immune-oncology education is needed in medical schools and beyond
![Stephen P. Schoenberger](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/stephen-p.-schoenberger/16103097-1-eng-GB/stephen-p.-schoenberger_i770.jpg)
Is there still a future for cancer vaccines?
Despite generally disappointing clinical trial results, technological innovations mean that realising the potential for cancer vaccines could be just around the corner